effects [qlco]
Oral [spco]
Estradiol [horm, phsu, strd]
Levonorgestrel [horm, phsu, strd]
CARDIOVASCULAR [bdsy]
Marker [clna]
postmenopausal [tmco]
Women [popg]
Study [mnob]
investigating [ftcn]
postmenopausal [tmco]
Women [popg]
CARDIOVASCULAR [bdsy]
Markers, Risk [qlco]
Induced [ftcn]
Hormone Therapy [topp]
regimens [inpr]
mg% [qnco]
ultra [medd]
mg% [qnco]
Doses [qnco]
micronized estradiol [orch, phsu]
Levonorgestrel [horm, phsu, strd]
randomized controlled trials [inpr, resa]
placebo [topp]
CARDIOVASCULAR [bdsy]
Markers, Risk [qlco]
Serum lipids NOS [lbpr]
Lipoproteins [aapp, bacs]
Coagulation [ortf]
Parameters [fndg]
Trial [resa]
Study [mnob]
effects [qlco]
mg% [qnco]
menopausal symptoms [sosy]
Trial [resa]
Study [mnob]
effects [qlco]
mg% [qnco]
Combined [qlco]
40 g [qnco]
Mu [inpr]
Levonorgestrel [horm, phsu, strd]
Endometrial [spco]
Safety [hcpp]
Trial [resa]
Study [mnob]
effects [qlco]
mg% [qnco]
40 g [qnco]
Mu [inpr]
Levonorgestrel [horm, phsu, strd]
bone metabolism [ortf]
mg% [qnco]
Reduced [qlco]
Low Density Lipoprotein Cholesterol [bacs, strd]
Little NOS [cgab, dsyn]
weeks [tmco]
mg% [qnco]
weeks [tmco]
lowered [spco]
Total Cholesterol [lbpr]
Addition [ftcn]
Levonorgestrel [horm, phsu, strd]
decreases [qnco]
Levels [qlco]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglycerides [bacs, lipd]
Dose-dependent [qnco]
mg% [qnco]
40 g [qnco]
Mu [inpr]
Levonorgestrel [horm, phsu, strd]
weeks [tmco]
lowered [spco]
Levels [qlco]
Total Cholesterol [lbpr]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglycerides [bacs, lipd]
regimens [inpr]
Slightly [idcn]
lowered [spco]
Antithrombin [aapp, phsu]
Protein C Activity [lbpr]
Normal limits [qnco]
Hormone Therapy [topp]
mg% [qnco]
Levonorgestrel [horm, phsu, strd]
Total Cholesterol [lbpr]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglycerides [bacs, lipd]
Affecting [ftcn]
Coagulation [ortf]
Fibrinolysis [phsf]
Parameters [fndg]
